Drug Risks Often Identified After FDA Approval
Sixty two percent of this specific drug class received the FDA’s most stringent warning, known as a “black box.” Most of the serious adverse effects were identified only after the drugs were on the market.
“It raises the question of should we be regulating them differently,” said Joseph Ross, an associate professor of medicine at Yale School of Medicine, who has studied drug safety. Read the full article here.
Podcast Series Features MISSD Board Member’s Akathisia Story
Experts by experience is a term increasingly used to describe healthcare consumers and their families who share factual, first-hand experiences relating to pharmaceutical products and doctors’ care. Gail Regenbogen, a MISSD board member, discusses her late husband, Howard’s, prescribed demise in our second Akathisia Stories podcast.
Please listen and share so that others can be safer and better informed regarding critical adverse drug effects. Gail eloquently tells her family’s story with profound wisdom acquired after Howard’s akathisia-induced death. Listen here.
MISSD Presents Akathisia Podcast Series
The power of sharing lived experiences is key to creating positive changes in health care. MISSD is pleased to release our first podcast in a series called “Akathisia Stories.” Please listen, learn & share here.
Elderly at Risk of Dementia as an Adverse Drug Effect
A recent study published in the JAMA Internal Medicine journal suggests the risk for dementia is strongest for certain classes of anticholinergic drugs — particularly antidepressants, bladder antimuscarinics, antipsychotics and antiepileptic drugs.
For the full article, click here.
Drug Safety for Pregnant Women & Nursing Moms
It’s often difficult for pregnant or breastfeeding women to obtain data regarding the safe use of prescription drugs, particularly given it can take more than 20 years to collect reliable safety info on drugs after they come to market. An international effort is underway to improve information in this critical area.
To read the full article, click here.
Spring Newsletter
It was a busy Spring for MISSD and we’re excited to share all our good news as well as our plans for a productive summer of programming and development. This includes a 100K grant, a royal presentation in London and a meaningful podcast series of personal stories all should hear.
Check out the link below for more info!
New Warning for Drugs Labeled Antidepressants
Today the European Medicines Agency (EMA) announced it is advising that commonly prescribed drugs called selective serotonin re-uptake inhibitors (SSRIs) should carry warnings that about the risks of long term sexual dysfunction as an adverse effect. Prozac, Zoloft and Paxil are just a few of many brand-name SSRIs.
To read the full article, click here.